Bank Of America Corp Aravive, Inc. Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.11 - $0.22 $3,928 - $7,857	-35,718 Reduced 99.9%	37 $0
Q1 2023 May 12, 2023	BUY	$1.29 - $2.46 $45,953 - $87,632	35,623 Added 26987.12%	35,755 $71,000
Q4 2022 Feb 10, 2023	BUY	$1.2 - $1.83 $67 - $102	56 Added 73.68%	132 $0
Q3 2022 Nov 14, 2022	BUY	$0.61 - $1.03 $6 - $10	10 Added 15.15%	76 $0
Q1 2022 May 16, 2022	SELL	$1.85 - $2.75 $9,682 - $14,393	-5,234 Reduced 98.75%	66 $0
Q4 2021 Feb 08, 2022	SELL	$2.19 - $4.07 $68,284 - $126,902	-31,180 Reduced 85.47%	5,300 $12,000
Q3 2021 Nov 15, 2021	BUY	$3.67 - $5.8 $60,298 - $95,294	16,430 Added 81.95%	36,480 $136,000
Q2 2021 Sep 13, 2021	BUY	$4.65 - $6.42 $93,232 - $128,721	20,050 New	20,050 $120,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.